Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort

By afschroeder • September 12, 2026

Wang S, Zhang Q, Jiang Z, Tong Z, Li W, Wang J, Ouyang Q, Yao T, Wang Y, Sun M, Wang X, Wang S, Zang A, Zhang Z, Chen W, Wang X, Li H, Sheng Y, Zhang B, Liu C, Zhao K, Munegowda MA, Bardia A, Xu B. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort. ESMO Open. 2026 Sep 11;11(10):108538. doi: 10.1016/j.esmoop.2026.108538. Epub ahead of print. PMID: 42727418.

Tags: China, Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, HR-positive breast cancer, HR+/HER2— breast cancer, Publications, TROPION-Breast01

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin[...]

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]